PubChemBreast cancerRoche presents details on breast cancer pill giredestrantRoche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San Antonio Breast Cancer Symposium. more ➔
adobe stock photos - deemerwhaFinancingDisco Pharmaceuticals GmbH expands seed financingCologne-based Disco Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers … more ➔
Tetraneuron SL - Álvaro GarcíaFinancingTetraneuron secures funding for Alzheimer’s gene therapy trialSpanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe. more ➔
Cellular Origins LtdFinancingCellular Origins secures major CGT funding breakthroughUK-bad Cellular Origins Ltd raised $40m to scale global CGT manufacturing with robotic automation, boosting access to cell therapies and enabling commercial growth. more ➔
SLASSLASSLAS announces finalists for the 2026 Ignite AwardThe Society for Laboratory Automation and Screening (SLAS) has unveiled the Ignite Award finalists: eight pioneering lab automation and drug discovery start-ups competing for $5,000 at SLAS 2026 in Boston, … more ➔
Formycon AGCancerGerman pure-play biosimilar developer Formycon agrees licensing and supply deal for U.S. and CanadaFormycon AG and Zydus Lifesciences Limited today jointly announced a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), … more ➔
Melt & Marble ABFinancingMelt&Marble secures €7.3m Series A to scale designer fatsSwedish Melt&Marble AB has raised €7.3m to scale precision-fermented designer fats for sustainable, high-performance food and personal care ingredients. more ➔
© peterschreiber. media - stock.adoImmunoncologyPoolbeg takes centre stage in CRS researchCancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company … more ➔
Orano Med SACancerOrano Med and Roche advance towards clinical programme in radiopharmacyOrano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production … more ➔
fvm.dkAgri-biotechEU trilogue sets clear path for new genomic techniquesAfter four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules … more ➔
PubChem
adobe stock photos - deemerwha
Tetraneuron SL - Álvaro García
Cellular Origins Ltd
SLAS
Formycon AG
Melt & Marble AB
© peterschreiber. media - stock.ado
Orano Med SA
fvm.dk